Clinical trial
Effect of Injection Site on the Relative and Absolute Bioavailability of Single Dose of LY900014 in Healthy Subjects
NCT03232983 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effect of Injection Site on the Relative and Absolute Bioavailability of Single Dose of LY900014 in Healthy Subjects
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 14, 2017
- Completion date
- November 9, 2017
- Enrollment
- 28 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.